Express Healthcare
Home  »  News  »  MedGenome labs to expand diagnostic portfolio through trident diagnostics acquisition

MedGenome labs to expand diagnostic portfolio through trident diagnostics acquisition

0 177
Read Article

This acquisition will help expand the access to tests to consumers in tier II and III markets

MedGenome Labs has acquired Trident Diagnostics & Healthcare. This partnership will help MedGenome further democratise genetic testing by providing integrated tests menu to clinicians, patients, and consumers across Karnataka.

Earlier this year, MedGenome Labs also ventured into direct-to-consumer (DTC) category under the brand name Genessense, offering specialized, evidence-based genetic screening tests that provide insights into a person’s health much before the onset of symptoms. This acquisition will help expand the access to these tests to consumers in Tier II and III markets.

Speaking on the acquisition, Dr Ramprasad, CEO, Diagnostics, MedGenome Labs, said, “At a time when coronavirus has turned the world’s attention towards genome sequencing and its role in timely prevention of infectious diseases, we are taking another step forward to convey the importance of genomics and personalized medicine in healthcare to larger population.

Kirandev Hiremath, Co-founder & Managing Director, Trident Diagnostics said, “It is indeed a big win for healthcare. With this acquisition, we will be working closely with MedGenome Labs, an established leader in the genetic diagnostic space. This will not only give us access to world-class technology but also assist us in research and development for creating faster, effective and accurate tests results that will contribute to providing better diagnosis with comprehensive test menu.”

In addition to all of the above capabilities, MedGenome will also work closely with the government and PSUs to bolster the nation’s needs in building better health systems.

Prof. Kshama Hiremath, Co-Founder & CEO, Trident Diagnostics said, “At a time when healthcare is the current backbone of any nation, this acquisition will also help India reach the pinnacle of diagnostics and tests in the future.”

Trident team was advised by Smark Capital a Bengaluru based transaction advisory firm. Smark Capital were the exclusive advisors to Trident management on this deal.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More